Exercise Neuroprotection in Parkinson's Disease

This study is looking into how exercise affects inflammation in people with Parkinson's disease (PD) and older adults. Researchers believe that inflammation in the brain (neuroinflammation) plays a big role in the death of brain cells in PD. By understanding how exercise impacts this inflammation, they hope to find ways to slow down or stop the disease from getting worse (neuroprotection). The study involves 90 participants, including people with PD and healthy older adults, who will engage in two different levels of a 30-minute aerobic exercise. The main goal is to see how exercise changes inflammation levels in the body. To join, you need to be between 30 and 85 years old, have a neurologist-diagnosed PD (if applicable), and be able to do 30 minutes of moderate aerobic exercise.

Study design
This is an interventional study with 90 planned participants. It involves two intensity levels of aerobic exercise, with participants trying both conditions.
What's involved
You would participate in two separate 30-minute aerobic exercise sessions, one week apart. Blood samples will be taken before and after each session.
Compensation
Not stated in the trial record.
Follow-up
Measurements are taken 30 minutes before and 30 minutes after each exercise session, with the two conditions separated by one week. There is no mention of follow-up beyond this.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05854524

Exercise Neuroprotection in Parkinson's Disease

Recruiting
NAAges 30–85InterventionalBasic science
University of Nevada, Las Vegas
~90 participants
Updated 2024-09-03 on ClinicalTrials.gov
What's tested:Aerobic exercise

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Exercise and inflammatory milieu
Measured over Baseline measurement only
+3 more outcomes measured
Parkinson Disease

NCT05854524

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Gait and Balance Laboratory, 217 Bigelow Health Sciences Building, UNLV

    Las Vegas, Nevadastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Merrill Landers, DPT, PhD · PRINCIPAL_INVESTIGATOR · University of Nevada, Las Vegas

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

30-85 years old
Neurologist-diagnosed PD
Able to participate in 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks per self-report.
30-85 years old
No major medical diagnoses
Able to participate in 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks per self-report.

Exclusion

Diagnoses, identified by self-report, that would preclude exercise participation (e.g., heart arrhythmias, uncontrolled blood pressure, exercise-induced asthma).
Those not deemed ready for exercise participation. Participants will be screened for exercise participation using the Physical Activities Readiness Questionnaire + which is used as a screening tool for all ages to identify risk factors that would clear someone for participation in moderate physical exercise.
Those with dementia will be excluded because there are self-report questionnaires in this study. This will be identified using the Montreal Cognitive Assessment and a score at or below a 21. Participants with mild cognitive impairment and no impairment will be included.
  • Exercise and inflammatory milieuBaseline measurement only

    International Physical Activity Questionnaire (IPAQ) and blood serum levels of the following: interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), interleukin-1β (IL-1β), interleukin-2 (IL-2), interleukin-10 (IL-10), c-reactive protein (CRP), RANTES, BDNF, VEGF, nerve growth factor (NGF), GDNF, Superoxide dismutase, catalase, glutathione peroxidase, total antioxidant capacity

  • Inflammatory milieu comparison to controlsBaseline measurement only

    Blood serum levels of the following: IL-6, TNF, IL-1β, IL-2, IL-10, CRP, RANTES, BDNF, VEGF, NGF, GDNF, Superoxide dismutase, catalase, glutathione peroxidase, total antioxidant capacity

  • Exercise dose and biomarkers30 minutes prior to the exercise (pre measurement) and 30 minutes after completing the 30-minute aerobic exercise condition (post measurement) . Both conditions are separated by one week.

    Change in blood serum levels of the following for the two different exercise conditions: IL-6, TNF, IL-1β, IL-2, IL-10, CRP, RANTES, BDNF, VEGF, NGF, GDNF, Superoxide dismutase, catalase, glutathione peroxidase, total antioxidant capacity, deglycase (DJ-1) protein, nonenzymatic antioxidants (Glutathione, Vitamin A, Vitamin C, Vitamin E).

  • Biomarkers in Parkinson Disease30 minutes prior to the exercise (pre measurement) and 30 minutes after completing the 30-minute aerobic exercise condition (post measurement) . Both conditions are separated by one week

    Change in blood serum levels of the following for people with Parkinson's disease and older adults: IL-6, TNF, IL-1β, IL-2, IL-10, CRP, RANTES, BDNF, VEGF, NGF, GDNF, Superoxide dismutase, catalase, glutathione peroxidase, total antioxidant capacity, DJ-1 protein, nonenzymatic antioxidants (Glutathione, Vitamin A, Vitamin C, Vitamin E).